NASDAQ:VYNE

Vyne Therapeutics Stock Signals

etoro logo Buy VYNE
*Your capital is at risk
$0.371
-0.0030 (-0.80%)
At Close: Nov 17, 2025

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -0.467 3 days ( -0.569 % )
Last Price $0.371 -0.80 %
High/ Low $0.361 - $0.399 14.52%
Chg 7 Days 3.77 % $0.358 $0.371
Chg 30 Days -1.80 % $0.378 $0.371
Chg 12 mos -86.24 % $2.70 $0.371
Trend - 3 mos 15.27 % Width: 36.96 %
Trend - 12 mos -67.25 % Width: 559.71 %
Pred. range - 3 mos $0.384 - $0.526 3.43 % - 41.66 %
Pred. range - 12 mos N/A - $0.504 -100.00 % - 35.73 %
Short MA avg 3 mos Buy Nov 05, 2025 - 9 days
Long MA avg 3 mos Buy Nov 12, 2025 - 4 days
Short/Long MA avg 3 mos Sell Nov 03, 2025 - 11 days
Short MA avg 12 mos Buy Nov 12, 2025 - 4 days
Long MA avg 12 mos Sell Jul 29, 2025 - 79 days
Short/Long MA avg 12 mos Sell Feb 10, 2025 - 195 days
Pivot Short Buy Oct 08, 2025 - 29 days
Bollinger Buy Oct 03, 2025 - 32 days
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!
ABOUT VYNE THERAPEUTICS INC
Vyne Therapeutics
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is als...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE